Literature DB >> 24550169

Towards an individualised target concentration of adalimumab in rheumatoid arthritis.

Emilie Ducourau1, David Ternant2, Thierry Lequerré3, Piéra Fuzibet1, Xavier Le Loët3, Hervé Watier4, Philippe Goupille1, Gilles Paintaud2, Olivier Vittecoq3, Denis Mulleman1.   

Abstract

Entities:  

Keywords:  Anti-TNF; Pharmacokinetics; Rheumatoid Arthritis

Mesh：

Substances：

Year:  2014        PMID： 24550169     DOI： 10.1136/annrheumdis-2013-204971

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  9 in total

1.  Golimumab Dried Blood Spot Analysis (GOUDA): a Prospective Trial Showing Excellent Correlation with Venepuncture Samples and More Detailed Pharmacokinetic Information.

Authors:  Iris Detrez; Ganel Schops; Jolien Lefrère; Sophie Tops; Gert Van Assche; Séverine Vermeire; Wouter Van Moerkercke; Marc Ferrante; Ann Gils
Journal:  AAPS J       Date:  2018-12-18       Impact factor: 4.009

Review 2.  Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.

Authors:  David Ternant; Theodora Bejan-Angoulvant; Christophe Passot; Denis Mulleman; Gilles Paintaud
Journal:  Clin Pharmacokinet       Date:  2015-11       Impact factor: 6.447

3.  CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis.

Authors:  Amina Bensalem; Denis Mulleman; Gilles Thibault; Nicolas Azzopardi; Philippe Goupille; Gilles Paintaud; David Ternant
Journal:  Br J Clin Pharmacol       Date:  2019-11-22       Impact factor: 4.335

Review 4.  Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider.

Authors:  Charlotte Krieckaert; Borja Hernández-Breijo; Johanna Elin Gehin; Guillaume le Mélédo; Alejandro Balsa; Meghna Jani; Denis Mulleman; Victoria Navarro-Compan; Gertjan Wolbink; John Isaac; Astrid van Tubergen
Journal:  RMD Open       Date:  2022-06

Review 5.  Judicious use of biologicals in juvenile idiopathic arthritis.

Authors:  Yongdong Zhao; Carol Wallace
Journal:  Curr Rheumatol Rep       Date:  2014-11       Impact factor: 4.592

6.  Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis.

Authors:  David Ternant; Emilie Ducourau; Piéra Fuzibet; Céline Vignault; Hervé Watier; Thierry Lequerré; Xavier Le Loët; Olivier Vittecoq; Philippe Goupille; Denis Mulleman; Gilles Paintaud
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

7.  Adalimumab concentration-based tapering strategy: as good as the recommended dosage.

Authors:  Denis Mulleman; Alejandro Balsa
Journal:  Ann Rheum Dis       Date:  2018-01-06       Impact factor: 19.103

Review 8.  Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases.

Authors:  Erwin Dreesen; Peter Bossuyt; Denis Mulleman; Ann Gils; Dora Pascual-Salcedo
Journal:  Clin Pharmacol       Date:  2017-10-03

9.  Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis.

Authors:  J Hiltunen; P Parmanne; T Sokka; T Lamberg; P Isomäki; O Kaipiainen-Seppänen; R Peltomaa; T Uutela; L Pirilä; K Taimen; M J Kauppi; T Yli-Kerttula; R Tuompo; H Relas; S Kortelainen; K Paalanen; J Asikainen; P Ekman; A Santisteban; K-L Vidqvist; K Tadesse; M Romu; J Borodina; P Elfving; H Valleala; M Leirisalo-Repo; V Rantalaiho; H Kautiainen; T S Jokiranta; K K Eklund
Journal:  Rheumatol Int       Date:  2021-08-06       Impact factor: 3.580
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.